Back to search results
NCT07439653

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Recruiting
PHASE1Ages 18+InterventionalTreatment
TORL Biotherapeutics, LLC
~155 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:TORL-5-700TORL-5-700 at MTD/RP2DTORL-5-700 at MTD/RP2D in combination with another agent

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate the safety of TORL-5-700 as a monotherapy
Measured over though study completion, an average of 2.5 years
+4 more outcomes measured

Conditions

Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Explore related trials

Diffuse Large B-Cell LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaNon-Hodgkin Lymphoma

NCT07439653

Where you'd take part

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Providence Medical Foundation

    Fullerton, Californiano site contact published

    Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennesseeno site contact published

    Recruiting

  • Stanford University

    Stanford, Californiano site contact published

    Recruiting

  • UCLA

    Santa Monica, Californiano site contact published

    Recruiting

  • University of Iowa Health Care

    Iowa City, Iowano site contact published

    Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texasno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Eric Park, M.D.
[email protected]
(310) 598-5969
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
At least 1 measurable lesion per Lugano criteria.
Tumor tissue is available.
Adequate organ function

Exclusion

T-cell lymphoma
CLL or SL
Burkitt lymphoma and high-grade B-cell lymphoma
CNS involvement
Peripheral neuropathy \> Grade 2
Uncontrolled medical conditions
Viral infections

What this trial measures

  • Evaluate the safety of TORL-5-700 as a monotherapythough study completion, an average of 2.5 years

    Assessment of adverse events according to NCI-CTCAE Version 5.0

  • Assess the antitumor activity of TORL-5-700 as monotherapythough study completion, an average of 2.5 years

    Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria

  • Evaluate the safety of TORL-5-700 in combination with other agentsthough study completion, an average of 2.5 years

    Assessment of adverse events according to NCI-CTCAE Version 5.0

  • Determine the Maximum Tolerated Dose (MTD)21 days from the start of treatment

    Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)

  • Determine the Recommended Phase 2 Dose (RP2D)21 days from the start of treatment

    Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities